News Release

Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team

Parsippany, NJ, October 2, 2008 – Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company’s management team. David St. Peter, M.D. joins Pacira as Vice President of Medical Education and Scientific Affairs. Dr. St. Peter was previously with inVentiv Health where he held several senior management positions since 2001, most recently serving on their Executive Team as president of The Selva Group, LLC, a medical education and event management company. In addition to industry positions at Marion Merrell Dow and Merck, Sharp & Dohme, he is in private practice and continues to see patients in the acute care setting as a Hospitalist.

“Dr. St. Peter brings a clear understanding of the critical elements required for successful late-phase market development in the institutional setting. In addition to working closely with our R&D, clinical and commercial teams as we prepare for a successful launch of DepoBupivacaine, we expect his contributions to be broad-based throughout Pacira’s overall commercial program,” commented chief executive officer Dave Stack.

Dr. St. Peter holds an M.D. from Kansas University Medical Center and a B.S. from the University of Kansas. He completed an internship in surgery at the University of Missouri and St. Lukes Hospital and a residency in medicine at Baptist Medical Center. He is an active member of the AMA, Society of Hospital Medicine, ACRP, APPI, AAFP, Alpha Omega Alpha, Global Alliance for Medical Education (GAME) and the American Medical Writers Association. St. Peter holds active medical licenses in two states and is board certified.

About Pacira
Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam® delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine™ in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt® for lymphomatous meningitis and DepoDur® for post-surgical pain. Additional information about Pacira is available at
www.pacira.com.

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.